According to Blockonomi, AstraZeneca PLC (AZN) stock increased by approximately 7% following reporting of financial results for the first nine months of the year. Revenue reached $46.9 billion during this period. Core earnings per share rose 14%, reaching $8, while operating profit for the nine-month period also increased. Oncology revenue grew 16% to $21.9 billion, representing the strongest growth among AstraZeneca’s therapy areas. The company secured 47 regional approvals for medicines, including four newly approved products. Guidance for 2026 remains unchanged, and plans for a 2027 pipeline continue as outlined previously.
